|
|
Article: NeoTherapeutics Expands Neotrofin(TM) Spinal Cord Injury Trial.
- Article from:
- PR Newswire
- Article date:
- June 29, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Phase 2 study in paraplegic and quadriplegic spinal cord
injury patients is set to begin enrollment at a second site
IRVINE, Calif., June 29 /PRNewswire/ --
NeoTherapeutics, Inc. (Nasdaq: NEOT; NEOTW) announced today that it has expanded its Neotrofin spinal cord injury trial to include Gaylord Hospital in Wallingford, Connecticut. Gaylord Hospital, which is affiliated with Yale University and the University of Connecticut, is the second site participating in the spinal cord injury trial. Additional sites are expected to join the study over the next couple of months. The 12-week open-label study of Neotrofin in patients with subacute complete ...